EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine
Who can join
Ages 18 to 64 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults aged 18 to 64 years * Diagnosis of migraine * Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation * Able and willing to provide informed consent * Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments Exclusion Criteria: * Age under 18 years * Pregnancy at the time of enrollment * Inability to provide informed consent * Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments * Insufficient clinical or patient-reported outcome data for the planned analyses
About the study
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.
What is being tested
- Middle Meningeal Artery Embolization (procedure)
Sponsor: Cortex Neurovascular · Participants: 50 · Started: Sep 1, 2026
Contact the study team
- Dennis Wang, Principal Investigator, MD · Phone: 253-284-0841
Official record on ClinicalTrials.gov — NCT07652034
Locations in the U.S.
| Washington | Cortex Neurovascular / TRA Union, Tacoma |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.